Study of inter- and intra-observer reproducibility in the interpretation of [18F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages 1-8

  Pegard, Clothilde ^a   Gallazzini Crépin, Céline ^b   Giai, Joris ^c   Dubreuil, Julien ^b   Caoduro, Cécile ^a   Desruet, Marie Dominique ^b   Roux, Julie ^b   Calizzano, Alex ^b   Fagret, Daniel ^b   Lamesa, Chloé ^b   Boulahdour, Hatem ^a   Vuillez, Jean Philippe ^b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b Centre Hospitalier et Universitaire de Grenoble   (France)

^c Centre d'Investigation Clinique   (France)

Author keywords

18F; Biochemical recurrence; choline positron emission tomography; Computed tomography; Inter and intra observer reproducibility; Prostate cancer

Indexed keywords

FUROSEMIDE;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIUM THERAPY; REPRODUCIBILITY;

EID: 84947045773     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-014-0025-7     Document Type: Article

References (19)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.Eur J Cancer Avr 2013, 49:1374–1403.
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012.CA Cancer J ClinFévr 2012, 62:10–29.
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.Eur Urol Janv 2011, 59:61–71.
4. Beuzeboc P, Words of wisdom: Re: defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.Eur Urol 2006, 50:1121–1122.
5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy.JAMA 1999, 281:1591–1597.
6. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.Int J Radiat Oncol Biol Phys 2006, 65:965–974.
7. Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, Thieme S, Cumming P, Klanke K, Tiling R, Bartenstein P, Hacker M: Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.Eur J Nucl Med Mol Imaging 2012, 39:271–282.
8. 11C]choline PET/CT in patients with biochemical failure after radical prostatectomy.Eur J Nucl Med Mol Imaging 2010, 37:301–309.
9. 11C-choline PET.J Nucl Med Off Publ Soc Nucl Med 2003, 44:331–335.
10. 11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.Eur Urol 2007, 52:423–429.
11. Landis JR, Koch GG: The measurement of observer agreement for categorical data.Biometrics 1977, 33:159–174.
12. Altman DG: Inter rater agreement. In Practical Statistics for Medical Research. London: Chapman & Hall/CRC; 1990:403–408.
13. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F: Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.Eur Urol 2011, 60:935–943.
14. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker H-C, Souvatzogluou M, Gildehaus FJ, Wester HJ, Dresel S: Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.Eur J Nucl Med Mol Imaging 2007, 34:45–53.
15. 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.Eur J Nucl Med Mol Imaging 2008, 35:976–983.
16. 11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.Clin Cancer Res Off J Am Assoc Cancer Res 2011, 17:3751–3759.
17. 11C]choline uptake in prostate cancer: a PET study.Eur J Nucl Med Mol Imaging 2004, 31:317–324.
18. 11C-choline PET/CT.Radiology 2007, 244:797–806.
19. 11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.Eur J Nucl Med Mol Imaging 2008, 35:9–17.